PaxMedica(PXMD) - 2023 Q1 - Quarterly Report

Financial Performance - Paxmedica, Inc. reported total operating expenses of approximately $4.0 million for the three months ended March 31, 2023, compared to $2.0 million for the same period in 2022, reflecting a 101.5% increase [121]. - General and administrative expenses increased by $2.9 million to approximately $3.8 million for the three months ended March 31, 2023, primarily due to $2.0 million in stock-based compensation [122]. - Research and development expenses decreased to approximately $0.2 million for the three months ended March 31, 2023, from approximately $1.1 million in the same period in 2022, a reduction of 80.7% [123]. - During the three months ended March 31, 2023, the company incurred a net loss of approximately $3.8 million, with net cash used in operating activities amounting to $3.0 million [131]. - Other income for the three months ended March 31, 2023, was approximately $0.2 million, a significant decrease from $3.8 million in the same period in 2022 [127]. Accumulated Deficit and Revenue - The accumulated deficit as of March 31, 2023, was approximately $37.6 million, with no revenue generated to date [107]. - As of March 31, 2023, the company had an accumulated deficit of approximately $37.6 million since inception and has not generated revenue from product sales [128]. Financing Activities - The company received net proceeds of approximately $2.6 million from the issuance of 1.2 million shares of common stock during the three months ended March 31, 2023 [111]. - A convertible promissory note (the "2023 Note") was issued with a principal balance of $3.7 million, providing proceeds of approximately $2.5 million, net of expenses [112]. - The company raised approximately $5.1 million from financing activities during the three months ended March 31, 2023, primarily from the issuance of convertible notes and common stock [135]. - The company issued a convertible promissory note with a principal balance of $3.7 million during the three months ended March 31, 2023, which bears no interest and matures in 18 months [130][140]. - The company received net proceeds of approximately $2.6 million from the issuance of 1.2 million shares of common stock in connection with its equity purchase agreement with Lincoln Park Capital during the three months ended March 31, 2023 [129]. Future Expectations - Paxmedica, Inc. expects to incur approximately $11.5 million in aggregate costs for research and development activities related to filing an NDA for Human African Trypanosomiasis (HAT) and an IND for Autism Spectrum Disorder (ASD) [126]. - The company anticipates significant increases in expenses related to ongoing development and commercialization efforts for PAX-101 and other product candidates [107]. - The company plans to seek additional financing through public or private equity or debt financings to support its operations [107]. - The company expects to continue incurring additional costs as a public company and may need to obtain substantial additional funding to support its operations [138][139]. - The company had a cash balance of approximately $4.0 million as of March 31, 2023, and anticipates incurring additional losses for the foreseeable future [137][138]. Liquidity and Risk - The company’s future liquidity and capital funding requirements will depend on various factors, including clinical trial results and the ability to maintain its intellectual property portfolio [138]. - The company does not engage in off-balance sheet financing arrangements and believes it is not materially exposed to financing, liquidity, market, or credit risk [141]. - The company has no investing activities reported for the three months ended March 31, 2023 and 2022 [134].